Eledon Pharmaceuticals prices $85M offering of common stock and pre-funded warrants at $3.65/share

Eledon Pharmaceuticals, Inc.

Gross proceeds ~$85M; net proceeds ~$79.5M after underwriting discounts and expenses.
Offering: 18,356,173 common shares at $3.65 plus pre-funded warrants for 4,931,507 shares at $3.649.
Investors include BVF Partners, RA Capital, Frazier Life Sciences, Blue Owl, First Light, Sphera, Woodline, Nantahala, and T1D Fund.
Proceeds to be used for advancing pipeline, working capital, and general corporate purposes.
Closing expected on or about October 30, 2024; 90-day lock-up for executives and directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.